Literature DB >> 15864803

Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells.

Yuko Yonezawa1, Yoji Nagashima, Hiromi Sato, Nantiga Virgona, Keiko Fukumoto, Sumiko Shirai, Hiromi Hagiwara, Taiichiro Seki, Toyohiko Ariga, Hironobu Senba, Kazuyuki Suzuki, Ryuji Asano, Kiyokazu Hagiwara, Tomohiro Yano.   

Abstract

Although the constitute activation of the Src family of kinases (Src) has been established as a poor prognostic factor in several types of cancer, the role of Src in renal cell carcinoma (RCC) has not been defined. This study aimed to determine whether Src could contribute to the appearance of malignant phenotypes in RCC. The role of Src in the appearance of malignant phenotypes in RCC was examined in two human renal cancer cell lines, Caki-1 from human metastatic RCC and ACHN from human primary RCC. Src activity in Caki-1 cells was higher than that in ACHN cells, and this difference corresponded to the difference of PP1 (a Src family inhibitor)-induced cytotoxicity on the two cells. The difference in cytotoxicity between the cells did not depend on cell cycle regulation but on the induction of apoptosis, and the difference in apoptosis particularly related to the reduction of the Bcl-xL level. Furthermore, in Caki-1 cells with higher Src activity, Src stimulated the production of vascular endothelial growth factor (VEGF), partially via the activation of Stat3, and the inhibition of Src activity caused a reduction of the VEGF level in serum, angiogenesis, and tumor development in a xenograft model. These results suggested that Src contributed to the appearance of malignant phenotypes in renal cancer cells, particularly due to the resistance against apoptosis by Bcl-xL and angiogenesis stimulated by Src-Stat3-VEGF signaling. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864803     DOI: 10.1002/mc.20109

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  12 in total

1.  MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.

Authors:  Shahana Majid; Sharanjot Saini; Altaf A Dar; Hiroshi Hirata; Varahram Shahryari; Yuichiro Tanaka; Soichiro Yamamura; Koji Ueno; Mohd Saif Zaman; Kamaldeep Singh; Inik Chang; Guoren Deng; Rajvir Dahiya
Journal:  Cancer Res       Date:  2011-02-17       Impact factor: 12.701

2.  LncRNA GATA3-AS1 promoted invasion and migration in human endometrial carcinoma by regulating the miR-361/ARRB2 axis.

Authors:  Yu-Xi Liu; Shuo Yuan; Xiao-Jing Liu; Yan-Xi Huang; Pin Qiu; Jie Gao; Gao-Pi Deng
Journal:  J Mol Med (Berl)       Date:  2022-07-05       Impact factor: 5.606

Review 3.  Gap junction and hemichannel-independent actions of connexins on cell and tissue functions--an update.

Authors:  Jade Z Zhou; Jean X Jiang
Journal:  FEBS Lett       Date:  2014-01-14       Impact factor: 4.124

4.  FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

5.  Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.

Authors:  Yasuo Awakura; Eijiro Nakamura; Takeshi Takahashi; Hirokazu Kotani; Yoshiki Mikami; Tadashi Kadowaki; Akira Myoumoto; Hideo Akiyama; Noriyuki Ito; Toshiyuki Kamoto; Toshiaki Manabe; Hitoshi Nobumasa; Gozoh Tsujimoto; Osamu Ogawa
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-16       Impact factor: 4.553

Review 6.  Regulation of renal cell carcinoma cell proliferation, invasion and metastasis by connexin 32 gene.

Authors:  H Sato; H Hagiwara; Y Ohde; H Senba; N Virgona; T Yano
Journal:  J Membr Biol       Date:  2007-06-13       Impact factor: 1.843

7.  5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene.

Authors:  H Hagiwara; H Sato; Y Ohde; Y Takano; T Seki; T Ariga; N Hokaiwado; M Asamoto; T Shirai; Y Nagashima; T Yano
Journal:  Br J Pharmacol       Date:  2008-02-11       Impact factor: 8.739

8.  A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis.

Authors:  Priyanka Kulkarni; Pritha Dasgupta; Yutaka Hashimoto; Marisa Shiina; Varahram Shahryari; Z Laura Tabatabai; Soichiro Yamamura; Yuichiro Tanaka; Sharanjot Saini; Rajvir Dahiya; Shahana Majid
Journal:  Cancer Res       Date:  2021-01-26       Impact factor: 13.312

9.  Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma.

Authors:  Kyu-Tae Kim; Hye Won Lee; Hae-Ock Lee; Hye Jin Song; Da Eun Jeong; Sang Shin; Hyunho Kim; Yoojin Shin; Do-Hyun Nam; Byong Chang Jeong; David G Kirsch; Kyeung Min Joo; Woong-Yang Park
Journal:  Genome Biol       Date:  2016-04-29       Impact factor: 13.583

10.  Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.

Authors:  Caroline Roelants; Sofia Giacosa; Catherine Pillet; Rémi Bussat; Pierre Champelovier; Olivier Bastien; Laurent Guyon; Valentin Arnoux; Claude Cochet; Odile Filhol
Journal:  Oncotarget       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.